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ABSTRACT
Background. The impact of cardiorespiratory comorbidity
on operative outcomes after esophagectomy remains con-
troversial. This study investigated the effect of
cardiorespiratory comorbidity on postoperative complica-
tions for patients treated for esophageal or
gastroesophageal junction cancer.
Patients and Methods. A European multicenter cohort
study from five high-volume esophageal cancer centers
including patients treated between 2010 and 2017 was
conducted. The effect of cardiorespiratory comorbidity and
respiratory function upon postoperative outcomes was
assessed.
Results. In total 1590 patients from five centers were
included; 274 (17.2%) had respiratory comorbidity, and
468 (29.4%) had cardiac comorbidity. Respiratory comor-
bidity was associated with increased risk of overall
postoperative complications, anastomotic leak, pulmonary
complications, pneumonia, increased Clavien–Dindo score,
and critical care and hospital length of stay. After neoad-
juvant chemoradiotherapy, respiratory comorbidity was
associated with increased risk of anastomotic leak [odds
ratio (OR) 1.83, 95% confidence interval (CI) 1.11–3.04],
pneumonia (OR 1.65, 95% CI 1.10–2.47), and any pul-
monary complication (OR 1.52, 95% CI 1.04–2.22), an
effect which was not observed following neoadjuvant
chemotherapy or surgery alone. Cardiac comorbidity was
associated with increased risk of cardiovascular and pul-
monary complications, respiratory failure, and Clavien–
Dindo score C IIIa. Among all patients, forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC)
ratio[ 70% was associated with reduced risk of overall
postoperative complications, cardiovascular complications,
atrial fibrillation, pulmonary complications, and
pneumonia.
Conclusions. The results of this study suggest that car-
diorespiratory comorbidity and impaired pulmonary
function are associated with increased risk of postoperative
complications after esophagectomy performed in high-
volume European centers. Given the observed interaction
with neoadjuvant approach, these data indicate a poten-
tially modifiable index of perioperative risk.
Surgical resection remains the mainstay of curative
treatment for esophageal cancer.1–3 Neoadjuvant therapy is
increasingly the standard of care for patients with locally
advanced disease, with neoadjuvant chemoradiotherapy in
the CROSS randomized controlled trial (RCT) achieving
5-year survival of 47%, establishing a modern benchmark
for treatment with curative intent.4 Moreover, the recent
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publication of the NeoFLOT data, and presentation of the
FLOT 4 trial data, including patients with adenocarcinoma
of the esophagogastric junction, highlighted real progress
in the curative management of this cancer with pre- and
postoperative chemotherapy.5,6
Notwithstanding this increased cure rate, esophagec-
tomy remains an exemplar of complex major surgery
associated with significant risk of major morbidity, and
substantial impact on health-related quality of life.7,8 In
this context, a number of strategies have been developed in
recent years to optimize the perioperative care of patients
and to minimize morbidity. These include enhanced
recovery after surgery (ERAS) protocols,9,10 and central-
ization of esophageal cancer surgery to high-volume
centers.11 In addition, the advent of total or hybrid mini-
mally invasive approaches to esophagectomy represents a
further advance, with a reduction in postoperative pul-
monary infections evidenced in recent randomized
trials.12,13
An area of controversy is whether the benefit of
improved oncologic outcomes from a combination
approach including neoadjuvant therapies is offset by an
increase in operative complications, in particular pul-
monary morbidity.11,14–17 In addition, whether preexisting
respiratory and cardiac comorbidity impacts on complica-
tions for each multimodality treatment approach is unclear.
Impaired pulmonary function, measured with spirometry, is
a known risk factor for postoperative complications.18
Accordingly, the primary objective of this study is to
evaluate the effect of cardiac and respiratory comorbidity
on postoperative complications and mortality. The sec-
ondary objective is to evaluate the role of preoperative
pulmonary function tests in identifying patients at risk of
postoperative complications and mortality, and to evaluate
the effects of cardiorespiratory comorbidity according to
treatment approach, either surgery alone, neoadjuvant
chemotherapy, or neoadjuvant chemoradiotherapy.
PATIENTS AND METHODS
Datasets
Data were collected from 2010 to 2017 from five high-
volume European esophageal cancer centers: (1) Karolin-
ska University Hospital, Stockholm, Sweden (n = 400), (2)
Imperial College London, UK (n = 137), (3) Academic
Medical Center, Amsterdam, The Netherlands (n = 575),
(4) Radboud University Medical Center, Nijmegen, The
Netherlands (n = 79), and (5) The National Esophageal and
Gastric Center, St. James’s Hospital, Dublin, Ireland
(n = 399).
Inclusion Criteria
All patients operated with curative intent for esophageal
or esophagogastric junction (EGJ) tumors (Siewert type I
and II) were included. Patients receiving surgery alone (S),
neoadjuvant chemotherapy (NCS), and neoadjuvant
chemoradiotherapy (NCRS) were studied. Patients receiv-
ing total minimally invasive, hybrid minimally invasive,
and open esophagectomy were included.
Exclusion Criteria
Patients found to have unresectable disease at time of
surgery, those with Siewert type III EGJ tumors, or
receiving definitive chemoradiotherapy followed by sal-
vage esophagectomy were excluded.
Clinical Staging and Follow-Up
Patients with histologically confirmed cancer of the
esophagus or EGJ were staged using endoscopy and posi-
tron emission tomography (PET)–computed tomography of
the thorax and abdomen, which was the standard practice at
all centers. Endoscopic ultrasound was used in the staging
of EGJ tumors at all centers. All centers had a standardized
postoperative pathway following esophagectomy, in
keeping with enhanced recovery after surgery (ERAS)
principles, though there was some minor heterogeneity
between centers.
Follow-up was similar between centers, with mortality
identified by linking institutional datasets with national
databases to ensure absolute accuracy of all-cause
mortality.
Outcomes Including Definition of Complications
The outcomes evaluated included 30-day and in-hospital
complications, which were defined as: postoperative res-
piratory failure requiring critical care admission,
postoperative atrial fibrillation requiring treatment,
according to postoperative Clavien–Dindo severity classi-
fication, anastomotic leakage or conduit necrosis
(endoscopically or radiographically verified), reoperation
for any cause, pneumonia defined by the individual
investigator when at least one of the following criteria were
fulfilled: new and persistent or progressive and persistent
radiographic infiltrate, and at least one of: fever ([ 38.0 C
or[ 100.4 F), leukopenia (B 4000 WBC/mm3), or
leukocytosis ([ 12,000 WBC/mm3), for adults[ 70 years
old, altered mental status with no other recognized cause,
and at least two of the following: new onset of purulent
sputum or change in character of sputum, or increased
respiratory secretions, or increased suctioning
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requirements, new-onset or worsening cough, or dyspnea,
or tachypnea, rales or bronchial breath sounds, worsening
gas exchange [e.g., O2 desaturations (e.g., PaO2/FiO2\
240)], increased oxygen requirements, or increased ven-
tilator demand.19 In-hospital, 30-day, and 90-day
postoperative all-cause mortality were compiled with
complete follow-up. Length of intensive care unit and
hospital stay were measured with complete follow-up.
Exposure
The exposure of the study was cardiac or respiratory
disease recorded at baseline. Respiratory disease was
defined as chronic pulmonary disease with impaired lung
function, including mild, moderate, or severe chronic
obstructive lung disease, pulmonary fibrosis, severe
asthma, or other chronic pulmonary disease assessed by the
surgeon at the initial consultation for esophageal cancer.
Cardiac disease was defined as chronic heart disease with
impaired cardiac function, including previous myocardial
infarction, congestive heart failure, or other chronic cardiac
disease assessed by the physician assessing the patient for
esophagectomy. Classification of comorbidities was per-
formed by the researcher based on the available clinical
data at each site (authors F. Klevebro, J. A. Elliott,
A. Slaman, B. D. Vermeulen, P. R. Boshier, and
S. R. Markar).
Covariates
Sex, age, weight, smoking status (smoker/nonsmoker/
ex-smoker), American Society of Anesthesiologists (ASA)
grade, Eastern Cooperative Oncology Group (ECOG)
performance status, and comorbidities including hyper-
tension and diabetes were collected. Preoperative results on
spirometry tests [FVC, FEV1, Tiffeneau–Pinelli index
(FEV1/FVC), bicycle or treadmill ergometry results
(measured in W/kg), and left ventricular ejection fraction
(LVEF) measured by echocardiogram (%)] were compiled
when available. Patients were stratified by FEV1/FVC
ratio[ 70%20 and LVEF[ 55%.21 Operative data
including surgical technique were gathered.
Statistical Analysis
The following confounders with categorizations were
used in the adjusted model for the main analysis: age
(continuous, years), gender [categorical: male (reference)/
female], histology [categorical: adenocarcinoma (refer-
ence)/squamous cell carcinoma], clinical T-stage
(categorical: 0–4), clinical N-stage (categorical: 0–3),
surgical technique [transthoracic esophagectomy according
to Ivor Lewis (reference), three-field esophagectomy
according to McKeown, or transhiatal esophagectomy],
and surgical approach [open (reference), hybrid minimally
invasive, or total minimally invasive esophagectomy].
For categorical outcomes, logistic regression models
were used to calculate odds ratios (OR) with 95% confi-
dence intervals (CI). All above-mentioned regression
models were adjusted for predefined confounders.
Approval was granted from the regional research ethics
committee of each participating center.
RESULTS
Comparison of Baseline Patient Demographics
and Pretreatment Tumor Stage
Preoperative Patient Demographics Significant
underlying differences in patient age, sex, and ASA score
were observed when comparing patients with and without
cardiorespiratory comorbidity (Table 1).
Pretreatment Tumor Characteristics and Surgical
Approach There were no statistically significant
differences in tumor stage, tumor type, or use of
neoadjuvant treatment between the groups, however
proximal tumor location was less common in the
cardiorespiratory comorbidity group (Table 1). Surgical
technique did show variation between the groups, with the
cardiorespiratory comorbidity group having a higher
proportion of transhiatal resections (22.1% vs. 11.4%,
P\ 0.001, Table 1).
Comparison of Postoperative Outcomes
Respiratory Comorbidity and Postoperative
Outcomes Preoperative respiratory comorbidity was
associated with an increase in postoperative
complications (70.8% vs. 64.4%), length of intensive care
unit stay (median 1 day vs. 0 days), and length of hospital
stay (median 18 days vs. 14 days). Postoperative Clavien–
Dindo complication scores were significantly increased
among patients with baseline respiratory comorbidity
(P = 0.037, Table 2). Multivariable adjusted analyses
showed an increased risk of anastomotic leak (OR 1.64,
95% CI 1.11–2.41) and pneumonia (OR 1.39, 95% CI
1.04–1.85, Table 3) among patients with baseline
respiratory comorbidity.
Cardiac Comorbidity Patients with preoperative cardiac
comorbidity had significantly increased risk of in-hospital
mortality (5.1% vs. 2.7%), anastomotic leak (15.6 vs.
11.3%), conduit necrosis (4.7% vs. 0.9%), cardiovascular
complications (27.6% vs. 17.7%), respiratory failure
2866 F. Klevebro et al.
TABLE 1 Unadjusted comparison of patient and treatment factors stratified by preoperative cardiorespiratory comorbidity status
N (%) No cardiorespiratory
comorbidity
(N = 982)
Respiratory
comorbidity
(N = 274)
Cardiac
comorbidity
(N = 468)
Cardiorespiratory
comorbidity
(N = 608)
P value*
Age (median, IQR), years 63 (56–70) 65 (60–71) 67 (62–72) 67 (61–71) \ 0.001
Sex 0.001
Male 739 (75.3) 219 (79.9) 392 (83.8) 500 (82.2)
Female 243 (24.8) 55 (20.1) 76 (16.2) 108 (17.8)
ASA score \ 0.001
1 7 (0.7) 26 (9.5) 24 (5.1) 46 (7.6)
2 345 (35.1) 160 (58.4) 270 (57.7) 356 (58.6)
3 515 (52.4) 87 (31.8) 171 (36.5) 203 (33.4)
4 113 (11.5) 1 (0.4) 3 (0.6) 3 (0.5)
ECOG score (n = 1264) 0.094
0 582 (70.7) 168 (74.0) 227 (69.4) 319 (72.3)
1 229 (27.8) 51 (22.5) 88 (26.9) 108 (24.5)
2 12 (1.5) 7 (3.1) 11 (3.4) 13 (3.0)
3 0 (0) 1 (0.4) 1 (0.3) 1 (0.2)
Smoking (n = 850) 0.086
Never 158 (34.4) 65 (28.4) 76 (27.2) 107 (27.4)
Former 211 (46.0) 104 (45.4) 157 (56.3) 200 (51.2)
Currently 90 (19.6) 60 (26.2) 46 (16.5) 84 (21.5)
FVC L, median (IQR) 4.1 (3.2–4.7) 3.7 (3.1–4.4) 3.8 (3.4–4.3) 3.7 (3.2–4.3) 0.008
FEV1 L, median (IQR) 2.9 (2.4–3.5) 2.4 (1.9–3.1) 2.8 (2.1–3.1) 2.6 (2.1–3.1) 0.020
FEV1/FVC median % (IQR)
(n = 850)
83.3 (74.3–97.0) 73.3 (63.2–82.6) 88.0 (75.9–100) 84 (71.7–98.0) 0.747
Bicycle test (W) (n = 34) No observations 129 (114–156) 131 (118–157) 131 (117–160)
Left ventricular ejection
fraction (%) (n = 234)
59.5 (55.0–63.0) 59 (55.0–60.0) 55 (50.0–60.0) 56.5 (53.0–60.0) 0.056
cT 0.127
1 111 (11.3) 44 (16.1) 62 (13.3) 81 (13.3)
2 173 (17.6) 42 (15.3) 75 (16.0) 103 (16.9)
3 614 (62.5) 168 (61.3) 308 (65.8) 392 (64.5)
4 48 (4.9) 12 (4.4) 10 (2.1) 18 (3.0)
X 36 (3.7) 8 (2.9) 13 (2.8) 14 (2.3)
cN 0.057
0 438 (44.6) 125 (45.6) 182 (38.9) 244 (40.1)
1 394 (40.1) 121 (44.2) 224 (47.9) 286 (47.0)
2 133 (13.5) 22 (8.0) 57 (12.2) 69 (11.4)
3 17 (1.7) 6 (2.2) 5 (1.1) 9 (1.5)
Tumor type 0.125
Adenocarcinoma 747 (76.1) 209 (76.3) 367 (78.2) 475 (78.1)
SCC 207 (21.1) 62 (22.6) 94 (20.1) 125 (20.6)
Other 28 (2.9) 3 (1.1) 7 (1.5) 8 (1.3)
Tumor location \ 0.001
Upper/middle 142 (14.5) 35 (12.8) 48 (10.3) 66 (10.9)
Distal 326 (33.2) 88 (32.1) 253 (54.1) 297 (48.9)
EGJ 514 (52.3) 151 (55.1) 167 (35.7) 245 (40.3)
Surgical approach 0.005
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(14.1% vs. 9.7%), reoperation for any cause (11.8% vs.
7.1%), and any pulmonary complication (42.7% vs.
34.9%). Postoperative Clavien–Dindo complication scores
were also increased with cardiac comorbidity (P\ 0.001,
Table 2). Multivariable adjusted analyses showed an
increased risk of cardiovascular complications (OR 1.63,
95% CI 1.25–2.13), pulmonary complications (OR 1.44,
95% CI 1.14–1.82), respiratory failure (OR 1.49, 95% CI
1.06–2.09), and Clavien–Dindo score C IIIa (OR 1.73,
95% CI 1.34–2.25, Table 3) among patients with
preoperative cardiac comorbidity.
Cardiorespiratory Comorbidity among Postoperative
Complications According to Neoadjuvant Protocol In a
multivariable adjusted analysis, respiratory comorbidity was
associated with increased risk of anastomotic leak (OR 1.83,
95% CI 1.11–3.04), pneumonia (OR 1.65, 95% CI 1.10–2.47),
and any pulmonary complication (OR 1.52, 95% CI
1.04–2.22) after neoadjuvant chemoradiotherapy but not
after neoadjuvant chemotherapy or surgery alone (Table 4).
Cardiac comorbidity was associated with increased risk
of cardiovascular complications, pulmonary complications,
and Clavien–Dindo score C IIIa regardless of neoadjuvant
treatment. In the neoadjuvant chemotherapy group, cardiac
comorbidity was associated with increased risk of in-hos-
pital mortality (OR 12.62, 95% CI 1.30–117.80, Table 4).
Preoperative Respiratory and Cardiac Investigations
and Postoperative Outcomes
Of 1590 patients, 608 (38.2%) had a cardiorespiratory
comorbidity, of whom 407 (66.9%) had documented
preoperative pulmonary function testing and 106 (17.4%)
had a preoperative echocardiogram. Ergometry results
were only available for 34 (5.6%) patients and were not
included in the analyses. Unadjusted analyses showed that
FEV1/FVC ratio[ 70% was associated with reduced
overall postoperative complications, cardiovascular com-
plications, atrial fibrillation, pulmonary complications, and
pneumonia. Adjusted analyses showed that FEV1/FVC
ratio[ 70% was associated with reduced risk of overall
postoperative complications (OR 0.57, 95% CI 0.37–0.89)
and atrial fibrillation (OR 0.46, 95% CI 0.28–0.75,
Table 5). LVEF[ 55% was associated with decreased risk
of anastomotic leak (adjusted OR 0.34, 95% CI 0.12–0.95),
but was otherwise unrelated to postoperative outcomes.
DISCUSSION
This large multicenter cohort study from high-volume
European academic centers highlights several important
points. First, cardiac or respiratory comorbidity substan-
tially increased the risk and severity of postoperative
complications, among patients deemed fit ab initio for
surgery. Second, impaired pulmonary function based on
spirometry reliably predicted pulmonary and cardiovascu-
lar complications, atrial fibrillation, pneumonia, and
overall postoperative complications. Third, neoadjuvant
chemoradiotherapy was associated with increased risk of
anastomotic leak and pulmonary complications among
patients with respiratory comorbidity, while neoadjuvant
chemotherapy or surgery alone was not.
TABLE 1 continued
N (%) No cardiorespiratory
comorbidity
(N = 982)
Respiratory
comorbidity
(N = 274)
Cardiac
comorbidity
(N = 468)
Cardiorespiratory
comorbidity
(N = 608)
P value*
Open 527 (53.7) 194 (70.8) 223 (47.7) 338 (55.6)
HMIO 36 (3.7) 5 (1.8) 5 (1.1) 6 (1.0)
TMIO 419 (42.7) 75 (27.4) 240 (51.3) 264 (43.4)
Surgical technique \ 0.001
Ivor Lewis 564 (57.5) 139 (51.1) 228 (48.8) 293 (48.4)
McKeown 305 (31.1) 62 (22.8) 140 (30.0) 179 (29.5)
Transhiatal 112 (11.4) 71 (26.1) 99 (21.2) 134 (22.1)
Neoadjuvant treatment 0.095
None 232 (23.6) 81 (29.6) 105 (22.4) 137 (22.5)
Chemotherapy 182 (18.5) 54 (19.7) 54 (11.5) 90 (14.8)
Chemoradiotherapy 568 (57.8) 139 (50.7) 309 (66.0) 381 (62.7)
IQR interquartile range, HMIO hybrid minimally invasive esophagectomy, TMIO totally minimally invasive esophagectomy, SCC squamous cell
carcinoma
*Comparing patients with and without preoperative cardiopulmonary disease
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Although risk assessment as part of modern manage-
ment and ERAS programs for esophageal surgery has
become increasingly standardized, accurate prediction of
risk remains a significant clinical challenge.11,17 Age alone
has not been associated with increased postoperative risk in
most studies.22,23 Higher ASA score and decreased per-
formance status are however established risk factors, and
this was confirmed in the present study (data not shown).11
Preoperative assessment using spirometry, or bicycle or
treadmill ergometry is commonly used to evaluate the
patient’s fitness to undergo esophagectomy.18,24 Interest-
ingly, however, even among academic centers,
approximately only two-thirds of patients with preopera-
tive cardiac or respiratory disease underwent such
evaluation in this time period. For those measures, FEV1/
FVC ratio[ 70% was independently associated with a
decreased risk of overall postoperative complications,
cardiovascular complications, atrial fibrillation, pulmonary
complications, and pneumonia. It seems prudent that all
patients undergoing treatment with curative intent for
esophageal cancer should undergo pulmonary physiology
studies, ideally before and after neoadjuvant therapy.
Cardiopulmonary exercise testing (CPET) applies analysis
of breath-by-breath expired gas data to evaluate car-
diorespiratory capacity. This test might provide a more
accurate and useful estimate of cardiorespiratory function
and risks associated with esophageal cancer treatment.25,26
The 6-min walk test is another test of cardiorespiratory
capacity and physical function, which have been shown to
predict perioperative risk in thoracic surgery.27,28 The role
of these tests in esophageal cancer treatment should be
evaluated in prospective studies and in trials of
prehabilitation.
Moreover, based on the present data, studies targeting
preoperative optimization through prehabilitation pro-
grams, including exercise interventions and smoking
cessation, to improve pulmonary function, have consider-
able therapeutic rationale. A randomized trial that assessed
TABLE 2 Comparison of postoperative outcomes stratified by preoperative cardiorespiratory comorbidity status
N (%) No cardiorespiratory
comorbidity
(N = 982)
Respiratory
comorbidity
(N = 274)
Cardiac
comorbidity
(N = 468)
Cardiorespiratory
comorbidity
(N = 608)
P value*
In-hospital mortality 28 (2.9) 12 (4.4) 24 (5.1)** 26 (4.3) 0.128
Postoperative complication 632 (64.4) 194 (70.8)** 305 (65.2) 408 (67.1) 0.263
Length of intensive care unit
stay, median days (IQR)
0 (0–2) 1 (0–5)** 1 (0–5) 1 (0–5)** \ 0.001
Length of hospital stay, median
days (IQR)
14 (10–22) 18 (12–30)** 15 (9–27) 15 (10–27) 0.057
Reoperation 48 (7.1) 20 (10.7) 47 (11.8)** 59 (11.4)** 0.010
Pneumonia 255 (26.0) 98 (35.8)** 136 (29.1) 180 (29.6) 0.114
Anastomotic leak 111 (11.3) 42 (15.3) 73 (15.6)** 86 (14.1) 0.095
Conduit necrosis 6 (0.9) 2 (2.7) 19 (4.7)** 19 (3.7)** 0.001
Cardiovascular complication 174 (17.7) 57 (20.9) 129 (27.6)** 153 (25.2)** \ 0.001
Atrial fibrillation 109 (11.1) 32 (11.7) 49 (10.5) 67 (11.0) 0.961
Respiratory failure 95 (9.7) 41 (15.0)** 66 (14.1)** 81 (13.3)** 0.024
Pulmonary complication 343 (34.9) 122 (44.5)** 200 (42.7)** 254 (41.8)** 0.006
Clavien–Dindo score – P = 0.037** P\ 0.001** P\ 0.001
Grade I 216 (28.0) 64 (26.7) 75 (26.9) 105 (22.8)
Grade II 231 (29.9) 68 (28.3) 76 (22.2) 114 (24.7)
Grade IIIa 143 (18.5) 27 (11.3) 46 (13.5) 64 (13.9)
Grade IIIb 56 (7.3) 22 (9.2) 19 (5.6) 30 (6.5)
Grade IVa 93 (12.1) 45 (18.8) 84 (24.6) 100 (21.7)
Grade IVb 25 (3.2) 13 (5.4) 26 (7.6) 32 (6.9)
Grade V 8 (1.0) 1 (0.42) 16 (4.7) 16 (3.5)
Clavien–Dindo score, median
(IQR)
II (I–IIIa) II (I–IIIb) IIIa (II–IVa) IIIa (II–IVa) \ 0.001
*Comparing patients with and without preoperative cardiopulmonary disease
**P\ 0.05 comparing patients with and without preoperative cardiopulmonary disease
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the effect of preoperative inspiratory muscle training
showed improved inspiratory muscle strength but no dif-
ference in lung function parameters or pulmonary
complications.29 A recent randomized controlled trial
showed that prehabilitation with an exercise program and
nutritional support significantly increased patients’ results
on the 6-min walk test.30 Preoperative optimization with
exercise, nutritional support, and the interaction with car-
diorespiratory comorbidity represent a highly pertinent
future research area.
In this study, cardiac comorbidity was associated with
increased in-hospital mortality after neoadjuvant
chemotherapy and esophagectomy. New-onset atrial fib-
rillation may be the most common specific complication
after esophagectomy, affecting approximately 20% of
patients.31 Preoperative treatment with 5-fluorouracil (5-
FU) and platins is known to cause cardiac sensitization.32 It
is interesting that this was not seen in the NCRS group, a
fact that might be explained by the differences in the
chemotherapy regimens which are used concomitant with
radiotherapy. Furthermore, cytotoxic agents may impair
myocellular proliferation by disrupting the mammalian
target of rapamycin kinase pathway,33 while cisplatin also
negatively impacts muscle function through a number of
mechanisms including impaired Akt phosphorylation,
leading to sustained activation of the degradative protea-
some and autophagy systems, and altered nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB)
signaling.34,35 Together these mechanisms may contribute
to myocardial dysfunction among patients treated with
preoperative chemotherapy.24,32 There was an increased
risk for anastomotic leak, pulmonary complications, and
pneumonia for patients with respiratory comorbidity after
NCRS but not after NCS. This could be an effect of the
added radiotherapy, which has been shown in previous
studies to be associated with increased risk for radiation
pneumonitis, reduced physical endurance, pulmonary dif-
fusion capacity, and heart function, and increased risk for
severe postoperative complications after esophagectomy
compared with NCS.14,17,36–42 Modern neoadjuvant
chemoradiotherapy regimens for esophageal cancer appear
to result in specific reductions in pulmonary diffusion
capacity, particularly among older adults and those with a
history of smoking or preexisting lung disease, which may
limit such patients’ ability to tolerate pulmonary morbidity,
increasing the risk of postoperative respiratory failure.42
Detailed analysis of postoperative outcomes is embedded
in ongoing randomized controlled trials comparing NCRS
with NCS for patients with esophageal adenocarci-
noma,43,44 and these secondary outcome measures will be
of critical importance, particularly if there is oncologic
equivalence.
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The limitations of this study include the retrospective
design and the difficulties in defining and measuring
postoperative outcomes, however it must be noted that
coding of complications was standardized for this study in
accordance with international consensus recommenda-
tions.45 The included patients have been evaluated
according to predefined variables by a devoted researcher
at each participating center to increase the internal validity
of the study. Pretreatment cardiac function tests were not
available in the majority of patients, and cardiorespiratory
comorbidity was assessed clinically. It is possible that
cardiorespiratory comorbidity status may have been mis-
classified in some patients. Pulmonary function tests
(PFTs) were however available in 67% of the patients. This
could lead to understatement of the positive associations in
the study, and prevents stratified analyses by type and
function of the cardiorespiratory comorbidities. The small
number of patients receiving preoperative cardiac investi-
gations prevented robust investigation of the link between
objective measurements of cardiac function and postoper-
ative outcome. Furthermore, diffusion capacity for carbon
monoxide (DLCO) was often not available, which pre-
vented meaningful analyses of the association with
postoperative complications which has been demonstrated
in previous research.46 Strengths of the study include the
standardized classification of complications, the large
sample size, and the multicenter design conferring external
validity to the study within high-volume European centers.
In conclusion, this study shows that cardiorespiratory
comorbidity is a clear risk factor for postoperative com-
plications after esophagectomy. Impaired preoperative lung
function is associated with increased risk of postoperative
complications, particularly following neoadjuvant
chemoradiotherapy. Careful clinical assessment, with
thorough investigation of cardiorespiratory function, is
required to facilitate treatment planning for patients con-
sidered for multimodal therapy for locally advanced
esophageal cancer.
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